Roivant Sciences (ROIV) Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ROIV shares.
View ROIV analyst ratings or view top-rated stocks.

8 analysts have issued twelve-month price targets for Roivant Sciences' shares. Their ROIV share price forecasts range from $10.00 to $23.00. On average, they anticipate the company's share price to reach $14.75 in the next twelve months. This suggests a possible upside of 42.8% from the stock's current price.
View analysts price targets for ROIV or view top-rated stocks among Wall Street analysts.

Roivant Sciences' stock was trading at $7.99 at the start of the year. Since then, ROIV shares have increased by 29.3% and is now trading at $10.33.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ROIV earnings forecast.

Roivant Sciences Ltd. (NASDAQ:ROIV) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.10. The business had revenue of $21.60 million for the quarter, compared to analyst estimates of $24.49 million. Roivant Sciences had a negative trailing twelve-month return on equity of 73.68% and a negative net margin of 1,233.11%. The company's revenue for the quarter was up 402.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.48) earnings per share.

ETFs with the largest weight of Roivant Sciences (NASDAQ:ROIV) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Moonshot Innovators ETF (MOON), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), Invesco Dorsey Wright Momentum ETF (PDP) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

Roivant Sciences trades on the NASDAQ under the ticker symbol "ROIV."

Roivant Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Patient Square Capital LP (1.65%), BlackRock Inc. (1.61%), State Street Corp (1.24%), Woodline Partners LP (0.50%), Rubric Capital Management LP (0.46%) and Perceptive Advisors LLC (0.41%). Insiders that own company stock include Eric Venker, Financial Lp Qvt, Global Investors Lp Viking, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar, Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy.
View institutional ownership trends.

Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ROIV stock can currently be purchased for approximately $10.33.

Roivant Sciences (NASDAQ:ROIV) has a market capitalization of $7.97 billion and generates $61.28 million in revenue each year. The company earns $-1,009,030,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

The company employs 904 workers across the globe.

Roivant Sciences' mailing address is Clarendon House, 2 Church Street, Hamilton Parish HM 11. The official website for the company is roivant.com. The company can be reached via phone at 44-20-7400-3347.